Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PRIORITY (Enpowering Progression Risk of Cerebral Amyloid Angiopathy)

NCT06960538 is registered in ClinicalTrials.gov with Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta as lead sponsor.

NCT NCT06960538
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06960538 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PRIORITY (Enpowering Progression Risk of Cerebral Amyloid Angiopathy)
Lead sponsor
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Phase
Observational
Overall status
Completed
Start date
November 1, 2021
Completion date
September 30, 2025
Enrollment
200 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

caa - cerebral amyloid angiopathy, cerebral amyloid angiopathy